Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Discontinuation of denosumab is associated with a rebound increase in osteoporotic fracture (OF) risk, and bisphosphonates (BPs) are commonly recommended as sequential therapy to mitigate this risk.